Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATYR aTyr Pharma	$5.99 +3.5%	$4.82	$1.58 ▼ $6.44	$515.34M	0.89	1.37 million shs	5.07 million shs
MCRB Seres Therapeutics	$14.07 -0.1%	$9.14	$6.53 ▼ $29.40	$122.95M	2.75	129,134 shs	85,712 shs
SIGA Siga Technologies	$6.61 -1.3%	$6.33	$4.95 ▼ $12.83	$478.65M	0.94	713,711 shs	274,054 shs
TRML Tourmaline Bio	$18.48 -0.6%	$17.15	$11.56 ▼ $29.79	$477.75M	2	254,407 shs	120,341 shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATYR aTyr Pharma	+3.45%	+13.02%	+15.86%	+93.23%	+254.44%
MCRB Seres Therapeutics	-0.07%	+11.93%	+82.02%	+90.14%	-52.47%
SIGA Siga Technologies	-1.34%	-2.36%	+2.96%	+10.35%	-26.64%
TRML Tourmaline Bio	-0.65%	+2.78%	+9.80%	+15.43%	+21.02%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATYR aTyr Pharma	2.5056 of 5 stars	3.6	1.0	0.0	3.5	1.7	0.6
MCRB Seres Therapeutics	3.4785 of 5 stars	2.9	1.0	4.6	3.8	0.8	0.0
SIGA Siga Technologies	2.0281 of 5 stars	0.0	3.0	0.0	1.5	0.8	3.1
TRML Tourmaline Bio	2.0139 of 5 stars	3.5	1.0	0.0	2.5	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATYR aTyr Pharma	3.14	Buy	$20.20	237.23% Upside
MCRB Seres Therapeutics	1.75	Reduce	$73.67	423.57% Upside
SIGA Siga Technologies	0.00	N/A	N/A	N/A
TRML Tourmaline Bio	3.00	Buy	$49.33	166.96% Upside

Current Analyst Ratings Breakdown

Latest MCRB, ATYR, SIGA, and TRML Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/20/2025	ATYR aTyr Pharma	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$17.00 ➝ $25.00
6/4/2025	ATYR aTyr Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$35.00
5/19/2025	ATYR aTyr Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$35.00 ➝ $35.00
5/8/2025	MCRB Seres Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$1.25 ➝ $6.00
5/5/2025	TRML Tourmaline Bio	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$70.00 ➝ $70.00
5/5/2025	TRML Tourmaline Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00 ➝ $50.00
4/23/2025	TRML Tourmaline Bio	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$70.00

(Data available from 7/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATYR aTyr Pharma	$230K	2,317.87	N/A	N/A	$0.83 per share	7.22
MCRB Seres Therapeutics	$126.32M	0.97	N/A	N/A	$1.61 per share	8.74
SIGA Siga Technologies	$138.72M	3.40	$0.83 per share	8.01	$3.02 per share	2.19
TRML Tourmaline Bio	N/A	N/A	N/A	N/A	$11.71 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATYR aTyr Pharma	-$64.02M	-$0.81	N/A	N/A	N/A	N/A	-87.09%	-64.77%	8/12/2025 (Estimated)
MCRB Seres Therapeutics	$140K	-$4.60	N/A	N/A	N/A	N/A	-41,084.76%	-55.87%	8/12/2025 (Estimated)
SIGA Siga Technologies	$59.21M	$0.67	9.87	5.29	N/A	40.30%	25.21%	22.05%	7/30/2025 (Estimated)
TRML Tourmaline Bio	-$73.21M	-$3.21	N/A	N/A	N/A	N/A	-26.75%	-26.11%	8/6/2025 (Estimated)

Latest MCRB, ATYR, SIGA, and TRML Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	TRML Tourmaline Bio	-$0.95	N/A	N/A	N/A	N/A	N/A
8/12/2025	Q2 2025	ATYR aTyr Pharma	-$0.18	N/A	N/A	N/A	N/A	N/A
8/12/2025	Q2 2025	MCRB Seres Therapeutics	-$2.72	N/A	N/A	N/A	N/A	N/A
5/8/2025	Q1 2025	SIGA Siga Technologies	N/A	-$0.01	N/A	-$0.01	N/A	$7.04 million
5/7/2025	Q1 2025	ATYR aTyr Pharma	-$0.19	-$0.17	+$0.02	-$0.17	N/A	N/A
5/7/2025	Q1 2025	MCRB Seres Therapeutics	-$0.67	-$2.24	-$1.57	$3.75	$10.00 million	N/A
5/2/2025	Q1 2025	TRML Tourmaline Bio	-$0.91	-$0.89	+$0.02	-$0.89	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATYR aTyr Pharma	N/A	N/A	N/A	N/A	N/A
MCRB Seres Therapeutics	N/A	N/A	N/A	N/A	N/A
SIGA Siga Technologies	N/A	N/A	N/A	N/A	N/A
TRML Tourmaline Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATYR aTyr Pharma	0.01	7.79	7.79
MCRB Seres Therapeutics	N/A	2.11	2.11
SIGA Siga Technologies	N/A	8.40	6.28
TRML Tourmaline Bio	N/A	33.87	33.87

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATYR aTyr Pharma	61.72%
MCRB Seres Therapeutics	59.34%
SIGA Siga Technologies	55.40%
TRML Tourmaline Bio	91.89%

Insider Ownership

Company	Insider Ownership
ATYR aTyr Pharma	3.70%
MCRB Seres Therapeutics	4.70%
SIGA Siga Technologies	1.95%
TRML Tourmaline Bio	13.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATYR aTyr Pharma	53	89.00 million	85.71 million	Optionable
MCRB Seres Therapeutics	330	8.73 million	8.32 million	Optionable
SIGA Siga Technologies	40	71.44 million	70.05 million	Optionable
TRML Tourmaline Bio	44	25.68 million	22.35 million	Optionable

MCRB, ATYR, SIGA, and TRML Headlines

Recent News About These Companies

Tourmaline Bio, Inc. (NASDAQ:TRML) Receives Consensus Rating of "Buy" from Brokerages

July 19 at 2:15 AM | marketbeat.com

Tourmaline Bio (NASDAQ:TRML) Shares Down 2.1% - Should You Sell?

July 16 at 4:29 AM | marketbeat.com

Tourmaline Bio Inc News (TRML) - Investing.com

July 3, 2025 | investing.com

TRML - Tourmaline Bio Inc Dividends - Morningstar

June 26, 2025 | morningstar.comM

TRML - Tourmaline Bio Inc Executives - Morningstar

June 24, 2025 | morningstar.comM

Tourmaline Bio, Inc. (NASDAQ:TRML) Receives Average Rating of "Buy" from Brokerages

June 24, 2025 | marketbeat.com

Tourmaline Bio Elects Directors and Ratifies Auditor

June 6, 2025 | tipranks.com

H.C. Wainwright maintains $50 target on Tourmaline Bio stock

May 29, 2025 | uk.investing.com

H.C. Wainwright Maintains Buy Rating on Tourmaline Bio (TRML) After Promising Phase 2 Results

May 29, 2025 | msn.com

BMO Sees Overreaction, Maintains Rating and Price Target on Tourmaline Bio (TRML)

May 23, 2025 | msn.com

Tourmaline shares waver as investors mull mid-stage pacibekitug data

May 21, 2025 | thepharmaletter.comT

Tourmaline touts cardiovascular potential of former Pfizer antibody after phase 2 kidney disease win

May 20, 2025 | fiercebiotech.comF

Tourmaline Bio posts mid-stage data for anti-inflammatory agent

May 20, 2025 | msn.com

Tourmaline Bio: TRANQUILITY Study Data Lends Credibility For IL-6 Inhibition

May 20, 2025 | seekingalpha.com

Tourmaline Bio to Present Topline Results from the Ongoing Phase 2 TRANQUILITY Trial of Pacibekitug on May 20, 2025

May 19, 2025 | globenewswire.com

Tourmaline Bio Reports Q1 2025 Financial Results

May 7, 2025 | tipranks.com

Why Tourmaline Bio, Inc.’s (TRML) Stock Is Down 7.00%

May 3, 2025 | aaii.comA

Tourmaline Bio, Inc.: Tourmaline Bio Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 3, 2025 | finanznachrichten.de

Tourmaline Bio Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 2, 2025 | globenewswire.com

Tourmaline Bio initiated with a Buy at Chardan

April 23, 2025 | markets.businessinsider.com

Tourmaline Bio (TRML) Gets a Buy from Chardan Capital

April 23, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MCRB, ATYR, SIGA, and TRML Company Descriptions

aTyr Pharma NASDAQ:ATYR

$5.99 +0.20 (+3.45%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$6.16 +0.18 (+2.92%)

As of 07/18/2025 07:58 PM Eastern

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Seres Therapeutics NASDAQ:MCRB

$14.07 -0.01 (-0.07%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$14.80 +0.73 (+5.22%)

As of 07/18/2025 07:50 PM Eastern

Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Siga Technologies NASDAQ:SIGA

$6.61 -0.09 (-1.34%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$6.61 0.00 (0.00%)

As of 07/18/2025 07:47 PM Eastern

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.

Tourmaline Bio NASDAQ:TRML

$18.48 -0.12 (-0.65%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$18.92 +0.45 (+2.41%)

As of 07/18/2025 05:14 PM Eastern

Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time